Innate immunity as a key element in host defense against methicillin resistant Staphylococcus aureus

Minerva Pediatrica

Volumn 61, Issue 5, 2009, Pages 503-514

  Harrison, C J ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Antimicrobial cationic peptides; C reactive protein; Immunity, innate; Methicillin resistant staphylococcus aureus; Reactive oxygen species

Indexed keywords

BACTERICIDIN; C REACTIVE PROTEIN; CATHELICIDIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATIONIC ANTIMICROBIAL PEPTIDE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; OPSONIN; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; BACTERIAL VIRULENCE; CD4+ T LYMPHOCYTE; COMPLEMENT ACTIVATION; DENDRITIC CELL; DERMIS; EPIDERMIS; HAIR FOLLICLE; HOST RESISTANCE; HUMAN; INNATE IMMUNITY; INTRACELLULAR KILLING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOCYTE; NEUTROPHIL; NEUTROPHIL EXTRACELLULAR TRAP; PHAGOCYTOSIS; PHAGOLYSOSOME; RECURRENT INFECTION; REVIEW; SEBACEOUS GLAND; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS TISSUE; SWEAT GLAND;

ANTIMICROBIAL CATIONIC PEPTIDES; C-REACTIVE PROTEIN; CHEMOTAXIS; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; IMMUNITY, INNATE; MACROPHAGES; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; NEUTROPHILS; REACTIVE OXYGEN SPECIES; STAPHYLOCOCCAL INFECTIONS; VIRULENCE;

EID: 75149173837     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Gorwitz RJ. Community-associated methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J. 2008;27:925-926.
2. Campbell SJ, Deshmukh HS, Nelson CL, Bae IG, Suyjewski ME, Federspiel JJ et al. Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. J Clin Microbiol 2008;46(2):678-684.
3. Palazzolo-Ballance AM, Reniere ML, Braugton KR, Sturdevant DE, Otto M, Kreiswirth BN et al. Neutrophil Microbicides Induce a Pathogen Survival Response in Community-Associated Methicillin-Resistant Staphylococcus aureus. J Immunol, 2008;180:500-509.
4. Texereau J, Chiche JD, Taylor W, Choukroun G, Comba B, Mira JP. The importance of Toll-like receptor 2 polymorphisms in severe infections. Clin Infect Dis 2005;41 Suppl 7:S408-S415.
5. Jann NJ, Schmaler M, Kristian SA, Radek KA, Gallo RL, Nizet V et al. Neutrophil antimicrobial defense against Staphylococcus aureus is mediated by phagolysosomal but not extracellular trap-associated cathelicidin. J Leukoc Biol 2009;86:000-000.
6. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol 2008;30(3):209-235.
7. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol 2007;120:13-22.
8. Niyonsaba F, Ogawa H. Protective roles of the skin against infection: Implication of naturally occurring human antimicrobial agents, -defensins, cathelicidin LL-37 and lysozyme. J Dermatol Science 2005;40:157-168.
9. Kupper TS, and Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004;4:211.
10. Bardan A, Nizet V, Gallo RL. Antimicrobial peptides and the skin. Expert Opin Biol Ther 2004;4:543.
11. Gudmundsson GH, Agerberth B, Odeberg J, Bergman T, Olsson B, Salcedo R.. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996;238:325.
12. Murakami M, Ohtake T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002;119:1090.
13. Murakami M, Lopez-Garcia B, Braff M, Dorschner RA, Gallo RL. Postsecretory processing generates multiple cathelicidins for enhanced topical antimicrobial defense. J Immunol 2004;172:3070.
14. Braff MH, Hawkins MA, Di Nardo A, Lopez-Garcia B, Howell MD, Wong C et al. Structure-Function Relationships among Human Cathelicidin Peptides: Dissociation of Antimicrobial Properties from Host Immunostimulatory Activities. J Immunology 2005;174:4271-4278.
15. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DYM. Endogenous Antimicrobial Peptides and Skin Infections in Atopic Dermatitis. 2002;347:1151-1160.
16. Howell, MD. The role of human beta defensins and cathelicidins in atopic dermatitis. Current Opinion in Allergy and Clinical Immunology 2007;7:413-417.
17. Hata TR, Kotol P, Jackson M, Nguyen M, Paik A, Udall D et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol. 2008;122(4):829-31.
18. Akiral S, Takedal K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunology 2001;2:675-680.
19. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004; 430: 258-263
20. Akira S, Uematsu S, Takeuchi O. Pathogen Recognition and Innate Immunity. Cell 2006;124(4):783-801.
21. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by Toll like receptor 2. J Biol Chem 1999;274:17406-17409.
22. Hoebe K, Georgel P, Rutschmann S, Du X, Mudd S, Crozat K et al. CD36 is a sensor of diacylglycerides. Nature 2005;433:523-527.
23. Schroder NW, Morath S, Alexander C, Hamann L, Hartung T, Zahringer U et al. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved. J Biol Chem 2003;278:15587-15594.
24. Schmaler M, Jann NJ, Ferracin F, Landolt LZ, Biswas L, Gotz F et al. Lipoproteins in Staphylococcus aureus mediate inflammation by TLR2 and iron-dependent growth in vivo. J Immunology 2009;182:7110-7118.
25. Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 2002;8:459-463.
26. Bubeck Wardenburg J, Williams WA, Missiakas D. Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc Natl Acad Sci USA 2006;103:13831-13836.
27. Takeuchi O, Hoshino K, Akira S. Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol 2000;165:5392-5396.
28. Schröder NWJ and Schumann RR. Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious disease. The Lancet Infectious Diseases 2005;5(3):156-164.
29. Volanakis JE. Human C-reactive protein: expression, structure, and function. Molecular Immunology 2001;38:189-197.
30. Du Clos TW. Function of C-reactive protein. Annals of Medicine 2000;32(4):274-8.
31. Amatayakul-Chantler S, Dwek RA, Tennent GA, Pepys MB, Rademacher TW. Molecular characterization of Limulus polyphemus C-reactive protein. II. Asparagine-linked oligosaccharides. Eur J Biochem 1993;15:214(1):99-110.
32. Li SP, Goldman ND. Regulation of Human C-Reactive Protein Gene Expression by Two Synergistic IL-6 Responsive Elements. Biochemistry 1996;35(28):9060- 9068.
33. Pepys MB, Hirschfield GM. Citation. C-reactive protein: a critical update. J Clin Invest 2003;111(12):1805-12.
34. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.
35. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-1363.
36. Volanakis JE. Complement activation by C-reactive protein complexes. Ann NY Acad Sci 1982;389:235-250.
37. Mold C, Gewürz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999;42:23-30.
38. Ferrari SL, Ahn-Luong L, Garnero P, Humphries SE, Greenspan SL. Two promoter polymorphisms regulating interleukin-6 gene expression are associated with circulating levels of C-reactive protein and markers of bone resorption in postmenopausal women. J Clin Endocrinol Metab 2003 Jan;88(1):255-9.
39. Hage FG, Szalai AJ. The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. Curr Atheroscler Rep 2009;11(2):124-30.
40. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS et al. Neutrophil extracellular traps kill bacteria. Science 2004;303:1532-1535.
41. Borregaard N, Cowland JB. Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 1997;89:3503-3521.
42. Komatsuzawa H, Ouhara K, Yamada S, Fujiwara T, Sayama K, Hashimoto K, et al. Innate defenses against methicillin-resistant Staphylococcus aureus (MRSA) infection. J Pathol 2006;208:249-260.
43. Segal AW. How neutrophils kill microbes. Annual Review of Immunology 2005;23:197-223.
44. Hampton MB, Kettle AJ, Winterbourn CC. Inside the Neutrophil Phagosome: Oxidants, Myeloperoxidase, and Bacterial Killing. Blood 1998;92:3007-3017.
45. Hand WL and King-Thompson NL. Membrane transport of clindamycin in alveolar macrophages. Antimicrob Agents Chemother. 1982;21:241-247.
46. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007;176:231-241.
47. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. JCB 2009;184:205-213.
48. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 2006;16:396-400.
49. Molloy, S. Bacterial pathogenesis: escaping the net. Nat Rev Microbiol2006;4:242-243.
50. Better K, Wartha F, Albiger B, Normark S, Zychlinsky A, Henriques-Normark B. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol 2006;16:401-407.
51. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V et al. Novel cell death program leads to neutrophil extracellular traps. JEM 2007;204:i2-2.
52. Clark RA, Malech HL, Gallin JI, et al. Genetic variants of chronic granulomatous disease: prevalence of deficiencies of two cytosolic components of me NADPH oxidase system. N Engl J Med 1989;321:647-652.
53. Assart T. Chronic Granulomatous Disease; fundamental stages in our understanding of CGD. Med Immunol 2006;5:4.
54. Yost CC, Cody MJ, Harris ES, Thornton NL, McInturff AM, Martinez ML et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood 2009;113:6419-6427.
55. Diep BA and Otto M. The role of virulence determinants in community-associated MRSA patfiogenesis. Trends in Microbiology.2008;16:361-369.